Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Biochim Biophys Acta ; 1862(9): 1521-32, 2016 09.
Article in English | MEDLINE | ID: mdl-27212416

ABSTRACT

Mounting evidence suggests that astrocyte activation, found in most forms of neural injury and disease, is linked to the hyperactivation of the protein phosphatase calcineurin. In many tissues and cell types, calcineurin hyperactivity is the direct result of limited proteolysis. However, little is known about the proteolytic status of calcineurin in activated astrocytes. Here, we developed a polyclonal antibody to a high activity calcineurin proteolytic fragment in the 45-48kDa range (ΔCN) for use in immunohistochemical applications. When applied to postmortem human brain sections, the ΔCN antibody intensely labeled cell clusters in close juxtaposition to amyloid deposits and microinfarcts. Many of these cells exhibited clear activated astrocyte morphology. The expression of ΔCN in astrocytes near areas of pathology was further confirmed using confocal microscopy. Multiple NeuN-positive cells, particularly those within microinfarct core regions, also labeled positively for ΔCN. This observation suggests that calcineurin proteolysis can also occur within damaged or dying neurons, as reported in other studies. When a similar ΔCN fragment was selectively expressed in hippocampal astrocytes of intact rats (using adeno-associated virus), we observed a significant reduction in the strength of CA3-CA1 excitatory synapses, indicating that the hyperactivation of astrocytic calcineurin is sufficient for disrupting synaptic function. Together, these results suggest that proteolytic activation of calcineurin in activated astrocytes may be a central mechanism for driving and/or exacerbating neural dysfunction during neurodegenerative disease and injury.


Subject(s)
Astrocytes/metabolism , Calcineurin/metabolism , Synapses/metabolism , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Animals , Antibody Specificity , Astrocytes/pathology , Brain/metabolism , Brain/pathology , Calcineurin/immunology , Cells, Cultured , Cerebral Infarction/metabolism , Cerebral Infarction/pathology , Humans , Immunohistochemistry , Male , Peptide Fragments/immunology , Peptide Fragments/metabolism , Proteolysis , Rats , Rats, Sprague-Dawley
2.
J Proteomics ; 74(11): 2430-40, 2011 Oct 19.
Article in English | MEDLINE | ID: mdl-21726674

ABSTRACT

Alzheimer disease (AD) is the most common type of dementia and is characterized pathologically by the presence of neurofibrillary tangles (NFTs), senile plaques (SPs), and loss of synapses. The main component of SP is amyloid-beta peptide (Aß), a 39 to 43 amino acid peptide, generated by the proteolytic cleavage of amyloid precursor protein (APP) by the action of beta- and gamma-secretases. The presenilins (PS) are components of the γ-secretase, which contains the protease active center. Mutations in PS enhance the production of the Aß42 peptide. To date, more than 160 mutations in PS1 have been identified. Many PS mutations increase the production of the ß-secretase-mediated C-terminal (CT) 99 amino acid-long fragment (CT99), which is subsequently cleaved by γ-secretase to yield Aß peptides. Aß has been proposed to induce oxidative stress and neurotoxicity. Previous studies from our laboratory and others showed an age-dependent increase in oxidative stress markers, loss of lipid asymmetry, and Aß production and amyloid deposition in the brain of APP/PS1 mice. In the present study, we used APP (NLh)/APP(NLh) × PS-1(P246L)/PS-1(P246L) human double mutant knock-in APP/PS-1 mice to identify specific targets of brain protein carbonylation in an age-dependent manner. We found a number of proteins that are oxidatively modified in APP/PS1 mice compared to age-matched controls. The relevance of the identified proteins to the progression and pathogenesis of AD is discussed.


Subject(s)
Alzheimer Disease/genetics , Amyloid beta-Protein Precursor/genetics , Brain/metabolism , Nerve Tissue Proteins/chemistry , Nerve Tissue Proteins/metabolism , Presenilin-1/genetics , Protein Carbonylation , Age Factors , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amino Acid Substitution/genetics , Amyloid beta-Protein Precursor/metabolism , Animals , Brain/pathology , Brain Chemistry , Disease Models, Animal , Gene Knock-In Techniques , Humans , Leucine/genetics , Male , Mice , Mice, Transgenic , Presenilin-1/chemistry , Presenilin-1/metabolism , Proline/genetics , Protein Structure, Tertiary/genetics , Proteomics/methods
3.
Mol Cell Pharmacol ; 2(1): 7-14, 2010 Jan 01.
Article in English | MEDLINE | ID: mdl-20401186

ABSTRACT

Nuclear factor of activated T cells (NFAT) is a transcription factor that translocates from cytosol to nucleus following dephosphorylation by the Ca(2+)/calmodulin dependent protein phosphatase calcineurin (CN). In nervous tissue, aberrant CN signaling is increasingly linked to a variety of pathologic features associated with Alzheimer's disease (AD), including synaptic dysfunction, glial activation, and neuronal death. Consistent with this linkage, our recent work on postmortem human hippocampal tissue discovered increased nuclear accumulation of select NFAT isoforms at different stages of AD. Some of these changes occurred at the early stages of the disease process and/or paralleled diminishing cognitive status. In addition, inhibition of astrocytic NFAT activity in primary cultures of neurons and glia dampened glutamate levels and alleviated neuronal death in response to pathogenic amyloid-ß peptides. In this article, we discuss our recent findings and expand upon the possible isoform specific contributions of NFATs to the progression of AD. We also consider the possible benefits of using NFAT inhibitors to treat AD and other neurodegenerative disorders, as well.

4.
J Neurosci ; 29(41): 12957-69, 2009 Oct 14.
Article in English | MEDLINE | ID: mdl-19828810

ABSTRACT

Upon activation by calcineurin, the nuclear factor of activated T-cells (NFAT) translocates to the nucleus and guides the transcription of numerous molecules involved in inflammation and Ca(2+) dysregulation, both of which are prominent features of Alzheimer's disease (AD). However, NFAT signaling in AD remains relatively uninvestigated. Using isolated cytosolic and nuclear fractions prepared from rapid-autopsy postmortem human brain tissue, we show that NFATs 1 and 3 shifted to nuclear compartments in the hippocampus at different stages of neuropathology and cognitive decline, whereas NFAT2 remained unchanged. NFAT1 exhibited greater association with isolated nuclear fractions in subjects with mild cognitive impairment (MCI), whereas NFAT3 showed a strong nuclear bias in subjects with severe dementia and AD. Similar to NFAT1, calcineurin-Aalpha also exhibited a nuclear bias in the early stages of cognitive decline. But, unlike NFAT1 and similar to NFAT3, the nuclear bias for calcineurin became more pronounced as cognition worsened. Changes in calcineurin/NFAT3 were directly correlated to soluble amyloid-beta (Abeta((1-42))) levels in postmortem hippocampus, and oligomeric Abeta, in particular, robustly stimulated NFAT activation in primary rat astrocyte cultures. Oligomeric Abeta also caused a significant reduction in excitatory amino acid transporter 2 (EAAT2) protein levels in astrocyte cultures, which was blocked by NFAT inhibition. Moreover, inhibition of astrocytic NFAT activity in mixed cultures ameliorated Abeta-dependent elevations in glutamate and neuronal death. The results suggest that NFAT signaling is selectively altered in AD and may play an important role in driving Abeta-mediated neurodegeneration.


Subject(s)
Calcineurin/metabolism , Cognition Disorders/etiology , Cognition Disorders/metabolism , NFATC Transcription Factors/metabolism , Signal Transduction/physiology , Aged , Aged, 80 and over , Alzheimer Disease/complications , Alzheimer Disease/metabolism , Amyloid beta-Peptides/pharmacology , Analysis of Variance , Animals , Astrocytes/drug effects , Brain/metabolism , Brain/pathology , Cells, Cultured , Cognition Disorders/pathology , Embryo, Mammalian , Female , Gene Expression Regulation/drug effects , Glial Fibrillary Acidic Protein/metabolism , Glutamic Acid/metabolism , Green Fluorescent Proteins/genetics , Hippocampus/cytology , Humans , Male , Peptide Fragments/pharmacology , Protein Transport/genetics , Rats , Transfection
5.
Free Radic Biol Med ; 45(10): 1420-5, 2008 Nov 15.
Article in English | MEDLINE | ID: mdl-18762245

ABSTRACT

Oxidative stress is strongly implicated in the progressive decline of cognition associated with aging and neurodegenerative disorders. In the brain, free radical-mediated oxidative stress plays a critical role in the age-related decline of cellular function as a result of the oxidation of proteins, lipids, and nucleic acids. A number of studies indicate that an increase in protein oxidation and lipid peroxidation is associated with age-related neurodegenerative diseases and cellular dysfunction observed in aging brains. Oxidative stress is one of the important factors contributing to Alzheimer's disease (AD), one of whose major hallmarks includes brain depositions of amyloid beta-peptide (Abeta) derived from amyloid precursor protein (APP). Mutation in APP and PS-1 genes, which increases production of the highly amyloidogenic amyloid beta-peptide (Abeta42), is the major cause of familial AD. In the present study, protein oxidation and lipid peroxidation in the brain from knock-in mice expressing human mutant APP and PS-1 were compared with brain from wild type, as a function of age. The results suggest that there is an increased oxidative stress in the brain of wild-type mice as a function of age. In APP/PS-1 mouse brain, there is a basal increase (at 1 month) in oxidative stress compared to the wild type (1 month), as measured by protein oxidation and lipid peroxidation. In addition, age-related elevation of oxidative damage was observed in APP/PS-1 mice brain compared to that of wild-type mice brain. These results are discussed with reference to the importance of Abeta42-associated oxidative stress in the pathogenesis of AD.


Subject(s)
Aging/physiology , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Brain/metabolism , Oxidative Stress , Presenilin-1/genetics , Presenilin-1/metabolism , Receptors, Cell Surface/genetics , Receptors, Cell Surface/metabolism , Aldehydes/metabolism , Amyloid beta-Peptides/metabolism , Animals , Humans , Lipid Peroxidation , Mice , Mice, Mutant Strains , Mutation , Peptide Fragments/metabolism , Protease Nexins
6.
J Biol Chem ; 283(32): 21953-64, 2008 Aug 08.
Article in English | MEDLINE | ID: mdl-18541537

ABSTRACT

Interleukin-1beta (IL-1beta) and the Ca(2+)/calmodulin-dependent protein phosphatase, calcineurin, have each been shown to play an important role in neuroinflammation. However, whether these signaling molecules interact to coordinate immune/inflammatory processes and neurodegeneration has not been investigated. Here, we show that exogenous application of IL-1beta (10 ng/ml) recruited calcineurin/NFAT (nuclear factor of activated T cells) activation in primary astrocyte-enriched cultures within minutes, through a pathway involving IL-1 receptors and L-type Ca(2+) channels. Adenovirus-mediated delivery of the NFAT inhibitor, VIVIT, suppressed the IL-1beta-dependent induction of several inflammatory mediators and/or markers of astrocyte activation, including tumor necrosis factor alpha, granulocyte/macrophage colony-stimulating factor, and vimentin. Expression of an activated form of calcineurin in one set of astrocyte cultures also triggered the release of factors that, in turn, stimulated NFAT activity in a second set of "naive" astrocytes. This effect was prevented when calcineurin-expressing cultures co-expressed VIVIT, suggesting that the calcineurin/NFAT pathway coordinates positive feedback signaling between astrocytes. In the presence of astrocytes and neurons, 48-h delivery of IL-1beta was associated with several excitotoxic effects, including NMDA receptor-dependent neuronal death, elevated extracellular glutamate, and hyperexcitable synaptic activity. Each of these effects were reversed or ameliorated by targeted delivery of VIVIT to astrocytes. IL-1beta also caused an NFAT-dependent reduction in excitatory amino acid transporter levels, indicating a possible mechanism for IL-1beta-mediated excitotoxicity. Taken together, the results have potentially important implications for the propagation and maintenance of neuroinflammatory signaling processes associated with many neurodegenerative conditions and diseases.


Subject(s)
Astrocytes/metabolism , Calcineurin/metabolism , Interleukin-1beta/metabolism , NFATC Transcription Factors/metabolism , Neurons/metabolism , Signal Transduction , Animals , Astrocytes/cytology , Astrocytes/drug effects , Calcium Channels, L-Type/metabolism , Cell Nucleus/metabolism , Cytosol/metabolism , Feedback, Physiological , Gene Expression Regulation/drug effects , Glutamate Plasma Membrane Transport Proteins/genetics , Interleukin-1beta/pharmacology , Neurons/drug effects , Protein Transport , Proteins/genetics , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects , Signal Transduction/immunology
7.
Neurobiol Dis ; 29(3): 456-64, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18077176

ABSTRACT

Oxidative stress, a hallmark of Alzheimer disease (AD), has been shown to induce lipid peroxidation and apoptosis disrupting cellular homeostasis. Normally, the aminophospholipid phosphatidylserine (PtdSer) is asymmetrically distributed on the cytosolic leaflet of the lipid bilayer. Under oxidative stress conditions, asymmetry is altered, characterized by the appearance of PtdSer on the outer leaflet, to initiate the first stages of an apoptotic process. PtdSer asymmetry is actively maintained by the ATP-dependent translocase flippase, whose function is inhibited if covalently bound by lipid peroxidation products, 4-hydroxynonenal (HNE) and acrolein, within the membrane bilayer in which they are produced. Additionally, pro-apoptotic proteins Bax and caspase-3 have been implemented in the oxidative modification of PtdSer resulting in subsequent asymmetric collapse, while anti-apoptotic protein Bcl-2 has been found to prevent this process. The current investigation focused on detection of PtdSer on the outer leaflet of the bilayer in synaptosomes from brain of subjects with AD and amnestic mild cognitive impairment (MCI), as well as expression levels of apoptosis-related proteins Bcl-2, Bax, and caspase-3. Fluorescence and Western blot analysis suggest PtdSer exposure on the outer leaflet is significantly increased in brain from subjects with MCI and AD contributing to early apoptotic elevation of pro- and anti-apoptotic proteins and finally neuronal loss. MCI is considered a possible transition point between normal cognitive aging and probable AD. Brain from subjects with MCI is reported to have increased levels of tissue oxidation; therefore, the results of this study could mark the progression of patients with MCI into AD. This study contributes to a model of apoptosis-specific oxidation of phospholipids consistent with the notion that PtdSer exposure is required for apoptotic-cell death.


Subject(s)
Alzheimer Disease/metabolism , Amnesia/metabolism , Apoptosis/physiology , Brain/metabolism , Cognition Disorders/metabolism , Phospholipids/metabolism , Aged , Aged, 80 and over , Alzheimer Disease/genetics , Alzheimer Disease/pathology , Amnesia/genetics , Amnesia/pathology , Animals , Brain/pathology , Cognition Disorders/genetics , Cognition Disorders/pathology , Female , Humans , Longitudinal Studies , Male , Mice , Oxidative Stress/physiology , Phosphatidylserines/genetics , Phosphatidylserines/metabolism , Phospholipids/chemistry
8.
Free Radic Biol Med ; 42(3): 371-84, 2007 Feb 01.
Article in English | MEDLINE | ID: mdl-17210450

ABSTRACT

Oxidative stress has been shown to underlie neuropathological aspects of Alzheimer's disease (AD). 4-Hydroxy-2-nonenal (HNE) is a highly reactive product of lipid peroxidation of unsaturated lipids. HNE-induced oxidative toxicity is a well-described model of oxidative stress-induced neurodegeneration. GSH plays a key role in antioxidant defense, and HNE exposure causes an initial depletion of GSH that leads to gradual toxic accumulation of reactive oxygen species. In the current study, we investigated whether pretreatment of cortical neurons with acetyl-L-carnitine (ALCAR) and alpha-lipoic acid (LA) plays a protective role in cortical neuronal cells against HNE-mediated oxidative stress and neurotoxicity. Decreased cell survival of neurons treated with HNE correlated with increased protein oxidation (protein carbonyl, 3-nitrotyrosine) and lipid peroxidation (HNE) accumulation. Pretreatment of primary cortical neuronal cultures with ALCAR and LA significantly attenuated HNE-induced cytotoxicity, protein oxidation, lipid peroxidation, and apoptosis in a dose-dependent manner. Additionally, pretreatment of ALCAR and LA also led to elevated cellular GSH and heat shock protein (HSP) levels compared to untreated control cells. We have also determined that pretreatment of neurons with ALCAR and LA leads to the activation of phosphoinositol-3 kinase (PI3K), PKG, and ERK1/2 pathways, which play essential roles in neuronal cell survival. Thus, this study demonstrates a cross talk among the PI3K, PKG, and ERK1/2 pathways in cortical neuronal cultures that contributes to ALCAR and LA-mediated prosurvival signaling mechanisms. This evidence supports the pharmacological potential of cotreatment of ALCAR and LA in the management of neurodegenerative disorders associated with HNE-induced oxidative stress and neurotoxicity, including AD.


Subject(s)
Acetylcarnitine/pharmacology , Cyclic GMP-Dependent Protein Kinases/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Nerve Degeneration/pathology , Neurons/drug effects , Oxidative Stress/drug effects , Phosphatidylinositol 3-Kinases/metabolism , Thioctic Acid/pharmacology , Aldehydes , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Animals , Apoptosis , Cell Survival , Cerebral Cortex/cytology , Cyclic GMP-Dependent Protein Kinases/antagonists & inhibitors , Enzyme Activation , Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors , Lipid Peroxidation , Nerve Degeneration/chemically induced , Neurons/metabolism , Neurons/pathology , Neuroprotective Agents/pharmacology , Oxidation-Reduction , Phosphoinositide-3 Kinase Inhibitors , Protein Kinase Inhibitors/pharmacology , Rats , Rats, Sprague-Dawley , Signal Transduction , Tyrosine/analogs & derivatives , Tyrosine/metabolism
9.
Exp Neurol ; 204(1): 29-38, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17069802

ABSTRACT

Human immunodeficiency virus dementia (HIVD) is the most common form of dementia occurring among young adults. In HIVD, neuronal cell loss occurs in the absence of neuronal infection. With the advent of highly active anti-retroviral therapy (HAART), the incidence of HIVD has drastically reduced, though prevalence of milder forms of HIVD continues to rise. Though these agents have been used successfully in suppressing viral production, they have also been associated with a number of side effects. Here we examine the possible role of NRTIs, in particular 2',3'-dideoxycytidine (ddC), in the neuropathology of HIVD. Synaptosomes and isolated mitochondria treated and incubated for 6 h with CSF-achievable concentrations of ddC, i.e., 6-11 ng/ml, were found to show a significant increase in oxidative stress with 40 nM ddC as measured by protein carbonyls and 3-nitrotyrosine (3NT), effects that were not observed in the more tolerable NRTI, 3TC. Protection against protein oxidation induced by ddC was observed when brain mitochondria were isolated from gerbils 1 h after injection i.p. with the brain accessible antioxidant and glutathione mimetic, tricyclodecan-9-yl-xanthogenate (D609). In addition, there is a significant reduction in the levels of anti-apoptotic protein Bcl-2 and a significant increase in cytochrome c release and also a significant increase in the expression of pro-apoptotic protein caspase-3 after mitochondria were treated with 40 nM ddC. The results reported here show that ddC at 40 nM can induce oxidative stress, cause the release of cytochrome c, and in addition, reduce the levels of anti-apoptotic proteins, increase the levels of pro-apoptotic proteins, thereby increasing the possibility for induction of apoptosis. These findings are consistent with the notion of a possible role of the NRTIs, and in particular, ddC, in the mechanisms involved in HIVD.


Subject(s)
Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Oxidative Stress , Reverse Transcriptase Inhibitors/pharmacology , Zalcitabine/pharmacology , AIDS Dementia Complex/drug therapy , AIDS Dementia Complex/metabolism , AIDS Dementia Complex/psychology , Animals , Antioxidants/pharmacology , Apoptosis , Bridged-Ring Compounds/pharmacology , Caspase 3/metabolism , Cytochromes c/metabolism , Disease Progression , Gerbillinae , Humans , Lamivudine/pharmacology , Male , Mitochondria/drug effects , Nerve Tissue Proteins/metabolism , Neuroprotective Agents/pharmacology , Norbornanes , Oxidation-Reduction/drug effects , Proto-Oncogene Proteins c-bcl-2/metabolism , Reverse Transcriptase Inhibitors/adverse effects , Synaptosomes/drug effects , Thiocarbamates , Thiones/pharmacology , Tyrosine/analogs & derivatives , Tyrosine/metabolism , bcl-2-Associated X Protein/metabolism
10.
Free Radic Biol Med ; 41(11): 1694-703, 2006 Dec 01.
Article in English | MEDLINE | ID: mdl-17145558

ABSTRACT

Tricyclodecan-9-yl-xanthogenate (D609) has in vivo and in vitro antioxidant properties. D609 mimics glutathione (GSH) and has a free thiol group, which upon oxidation forms a disulfide. The resulting dixanthate is a substrate for glutathione reductase, regenerating D609. Recent studies have also shown that D609 protects brain in vivo and neuronal cultures in vitro against the potential Alzheimer's disease (AD) causative factor, Abeta(1-42)-induced oxidative stress and cytotoxicity. Mitochondria are important organelles with both pro- and antiapoptotic factor proteins. The present study was undertaken to test the hypothesis that intraperitoneal injection of D609 would provide neuroprotection against free radical-induced, mitochondria-mediated apoptosis in vitro. Brain mitochondria were isolated from gerbils 1 h post injection intraperitoneally (ip) with D609 and subsequently treated in vitro with the oxidants Fe(2+)/H(2)O(2) (hydroxyl free radicals), 2,2-azobis-(2-amidinopropane) dihydrochloride (AAPH, alkoxyl and peroxyl free radicals), and AD-relevant amyloid beta-peptide 1-42 [Abeta(1-42)]. Brain mitochondria isolated from the gerbils previously injected ip with D609 and subjected to these oxidative stress inducers, in vitro, showed significant reduction in levels of protein carbonyls, protein-bound hydroxynonenal [a lipid peroxidation product], 3-nitrotyrosine, and cytochrome c release compared to oxidant-treated brain mitochondria isolated from saline-injected gerbils. D609 treatment significantly maintains the GSH/GSSG ratio in oxidant-treated mitochondria. Increased activity of glutathione S-transferase, glutathione peroxidase, and glutathione reductase in brain isolated from D609-injected gerbils is consistent with the notion that D609 acts like GSH. These antiapoptotic findings are discussed with reference to the potential use of this brain-accessible glutathione mimetic in the treatment of oxidative stress-related neurodegenerative disorders, including AD.


Subject(s)
Amyloid beta-Peptides/adverse effects , Antioxidants/administration & dosage , Brain/drug effects , Bridged-Ring Compounds/administration & dosage , Mitochondria/drug effects , Oxidative Stress , Thiones/administration & dosage , Alzheimer Disease , Animals , Apoptosis/drug effects , Brain/cytology , Brain/metabolism , Cytochromes c/metabolism , Gerbillinae , Glutathione/metabolism , Glutathione Peroxidase/metabolism , Glutathione Reductase/metabolism , Glutathione Transferase/metabolism , Injections, Intraperitoneal , Lipid Peroxidation , Male , Mitochondria/metabolism , Neurodegenerative Diseases , Neuroprotective Agents/pharmacology , Norbornanes , Oxidation-Reduction , Thiocarbamates , Type C Phospholipases/antagonists & inhibitors , Tyrosine/analogs & derivatives , Tyrosine/metabolism
11.
J Neurochem ; 98(6): 1697-706, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16945100

ABSTRACT

Proteolytic processing and phosphorylation of amyloid precursor protein (APP), and hyperphosphorylation of tau protein, have been shown to be increased in Alzheimer's disease (AD) brains, leading to increased production of beta-amyloid (Abeta) peptides and neurofibrillary tangles, respectively. These observations suggest that phosphorylation events are critical to the understanding of the pathogenesis and treatment of this devastating disease. Pin-1, one of the peptidyl-prolyl isomerases (PPIase), catalyzes the isomerization of the peptide bond between pSer/Thr-Pro in proteins, thereby regulating their biological functions which include protein assembly, folding, intracellular transport, intracellular signaling, transcription, cell cycle progression and apoptosis. A number of previous studies have shown that Pin1 is co-localized with phosphorylated tau in AD brain, and shows an inverse relationship to the expression of tau. Pin1 protects neurons under in vitro conditions. Moreover, recent studies demonstrate that APP is a target for Pin1 and thus, in Abeta production. Furthermore, Pin1 was found to be oxidatively modified and to have reduced activity in the hippocampus in mild cognitive impairment (MCI) and AD. Because of the diverse functions of Pin1, and the discovery that this protein is one of the oxidized proteins common to both MCI and AD brain, the question arises as to whether Pin1 is one of the driving forces for the initiation or progression of AD pathogenesis, finally leading to neurodegeneration and neuronal apoptosis. In the present review, we discuss the role of Pin1 with respect to Alzheimer's disease.


Subject(s)
Alzheimer Disease/metabolism , Peptidylprolyl Isomerase/metabolism , Alzheimer Disease/genetics , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Animals , Apoptosis , Brain/metabolism , Cell Cycle , Cognition Disorders/metabolism , Cognition Disorders/psychology , Cytokines/metabolism , DNA Damage , Humans , NF-kappa B/metabolism , NIMA-Interacting Peptidylprolyl Isomerase , Oxidation-Reduction , Peptidylprolyl Isomerase/chemistry , Severity of Illness Index , Structure-Activity Relationship
12.
NeuroRx ; 3(3): 344-57, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16815218

ABSTRACT

Neurodegenerative diseases cause memory loss and cognitive impairment. Results from basic and clinical scientific research suggest a complex network of mechanisms involved in the process of neurodegeneration. Progress in treatment of such disorders requires researchers to better understand the functions of proteins involved in neurodegenerative diseases, to characterize their role in pathogenic disease mechanisms, and to explore their roles in the diagnosis, treatment, and prevention of neurodegenerative diseases. A variety of conditions of neurodegenerative diseases often lead to post-translational modifications of proteins, including oxidation and nitration, which might be involved in the pathogenesis of neurodegenerative diseases. Redox proteomics, a subset of proteomics, has made possible the identification of specifically oxidized proteins in neurodegenerative disorders, providing insight into a multitude of pathways that govern behavior and cognition and the response of the nervous system to injury and disease. Proteomic analyses are particularly suitable to elucidate post-translational modifications, expression levels, and protein-protein interactions of thousands of proteins at a time. Complementing the valuable information generated through the integrative knowledge of protein expression and function should enable the development of more efficient diagnostic tools and therapeutic modalities. Here we review redox proteomic studies of some neurodegenerative diseases.


Subject(s)
Aging/physiology , Models, Biological , Neurodegenerative Diseases/metabolism , Proteomics , Aged , Animals , Cognition Disorders/etiology , Cognition Disorders/metabolism , Databases as Topic , Electrophoresis, Gel, Two-Dimensional , Humans , Mass Spectrometry , Neurodegenerative Diseases/complications , Neurodegenerative Diseases/physiopathology , Oxidation-Reduction
13.
J Neurosci Res ; 84(2): 398-408, 2006 Aug 01.
Article in English | MEDLINE | ID: mdl-16634066

ABSTRACT

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by loss of memory and cognition and by senile plaques and neurofibrillary tangles in brain. Amyloid-beta peptide, particularly the 42-amino-acid peptide (Abeta(1-42)), is a principal component of senile plaques and is thought to be central to the pathogenesis of the disease. The AD brain is under significant oxidative stress, and Abeta(1-42) peptide is known to cause oxidative stress in vitro and in vivo. Acetyl-L-carnitine (ALCAR) is an endogenous mitochondrial membrane compound that helps to maintain mitochondrial bioenergetics and lowers the increased oxidative stress associated with aging. Glutathione (GSH) is an important endogenous antioxidant, and its levels have been shown to decrease with aging. Administration of ALCAR increases cellular levels of GSH in rat astrocytes. In the current study, we investigated whether ALCAR plays a protective role in cortical neuronal cells against Abeta(1-42)-mediated oxidative stress and neurotoxicity. Decreased cell survival in neuronal cultures treated with Abeta(1-42) correlated with an increase in protein oxidation (protein carbonyl, 3-nitrotyrosine) and lipid peroxidation (4-hydroxy-2-nonenal) formation. Pretreatment of primary cortical neuronal cultures with ALCAR significantly attenuated Abeta(1-42)-induced cytotoxicity, protein oxidation, lipid peroxidation, and apoptosis in a dose-dependent manner. Addition of ALCAR to neurons also led to an elevated cellular GSH and heat shock proteins (HSPs) levels compared with untreated control cells. Our results suggest that ALCAR exerts protective effects against Abeta(1-42) toxicity and oxidative stress in part by up-regulating the levels of GSH and HSPs. This evidence supports the pharmacological potential of acetyl carnitine in the management of Abeta(1-42)-induced oxidative stress and neurotoxicity. Therefore, ALCAR may be useful as a possible therapeutic strategy for patients with AD.


Subject(s)
Acetylcarnitine/pharmacology , Alzheimer Disease/metabolism , Amyloid beta-Peptides/toxicity , Heat-Shock Proteins/metabolism , Neurons/drug effects , Neuroprotective Agents/pharmacology , Animals , Blotting, Western , Cells, Cultured , Cerebral Cortex/drug effects , Cerebral Cortex/pathology , DNA Fragmentation , Glutathione/drug effects , Glutathione/metabolism , Heat-Shock Proteins/drug effects , Lipid Peroxidation/drug effects , Neurons/metabolism , Oxidation-Reduction/drug effects , Oxidative Stress/drug effects , Oxidative Stress/physiology , Proteins/drug effects , Rats , Rats, Sprague-Dawley , Up-Regulation
14.
J Neurosci Res ; 84(2): 409-17, 2006 Aug 01.
Article in English | MEDLINE | ID: mdl-16634065

ABSTRACT

Oxidative stress has been implicated in the pathophysiology of a number of diseases, including neurodegenerative disorders such as Alzheimer's disease (AD), a neurodegenerative disorder associated with cognitive decline and enhanced oxidative stress. Amyloid-beta peptide(1-42) (Abeta(1-42)), one of the main component of senile plaques, can induce in vitro and in vivo oxidative damage to neuronal cells through its ability to produce free radicals. The aim of this study was to investigate the protective effect of the xanthate D609 on Abeta(1-42)-induced protein oxidation by using a redox proteomics approach. D609 was recently found to be a free radical scavenger and antioxidant. In the present study, rat primary neuronal cells were pretreated with 50 microM of D609, followed by incubation with 10 microM Abeta(1-42) for 24 hr. In the cells treated with Abeta(1-42) alone, four proteins that were significantly oxidized were identified: glyceraldehyde-3-phosphate dehydrogenase, pyruvate kinase, malate dehydrogenase, and 14-3-3 zeta. Pretreatment of neuronal cultures with D609 prior to Abeta(1-42) protected all the identified oxidized proteins in the present study against Abeta(1-42)-mediated protein oxidation. Therefore, D609 may ameliorate the Abeta(1-42)-induced oxidative modification. We discuss the implications of these Abeta(1-42)-mediated oxidatively modified proteins for AD pathology and for potential therapeutic intervention in this dementing disorder.


Subject(s)
Amyloid beta-Peptides/toxicity , Bridged-Ring Compounds/pharmacology , Neurons/drug effects , Neuroprotective Agents/pharmacology , Proteomics , Thiones/pharmacology , 14-3-3 Proteins/drug effects , 14-3-3 Proteins/metabolism , Alzheimer Disease/physiopathology , Animals , Cells, Cultured , Glyceraldehyde-3-Phosphate Dehydrogenases/drug effects , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Image Processing, Computer-Assisted , Malate Dehydrogenase/drug effects , Malate Dehydrogenase/metabolism , Mass Spectrometry , Neurons/metabolism , Norbornanes , Oxidation-Reduction/drug effects , Protein Carbonylation/drug effects , Pyruvate Kinase/drug effects , Rats , Rats, Sprague-Dawley , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Thiocarbamates
15.
J Neurosci Res ; 79(5): 700-6, 2005 Mar 01.
Article in English | MEDLINE | ID: mdl-15678514

ABSTRACT

Glutathione (GSH) is an important endogenous antioxidant found in millimolar concentrations in the brain. GSH levels have been shown to decrease with aging. Alzheimer's disease (AD) is a neurodegenerative disorder associated with aging and oxidative stress. Abeta(1-42) has been shown to induce oxidative stress and has been proposed to play a central role in the oxidative damage detected in AD brain. It has been shown that administration of gamma-glutamylcysteine ethyl ester (GCEE) increases cellular levels of GSH, circumventing the regulation of GSH biosynthesis by providing the limiting substrate. In this study, we evaluated the protective role of up-regulation of GSH by GCEE against the oxidative and neurotoxic effects of Abeta(1-42) in primary neuronal culture. Addition of GCEE to neurons led to an elevated mean cellular GSH level compared with untreated control. Inhibition of gamma-glutamylcysteine synthetase by buthionine sulfoximine (BSO) led to a 98% decrease in total cellular GSH compared with control, which was returned to control levels by addition of GCEE. Taken together, these results suggest that GCEE up-regulates cellular GSH levels which, in turn, protects neurons against protein oxidation, loss of mitochondrial function, and DNA fragmentation induced by Abeta(1-42). These results are consistent with the notion that up-regulation of GSH by GCEE may play a viable protective role in the oxidative and neurotoxicity induced by Abeta(1-42) in AD brain.


Subject(s)
Amyloid beta-Peptides/toxicity , Dipeptides/pharmacology , Glutathione/metabolism , Neurons/drug effects , Oxidative Stress/drug effects , Peptide Fragments/toxicity , Up-Regulation/drug effects , Alzheimer Disease/drug therapy , Amyloid/ultrastructure , Amyloid beta-Peptides/antagonists & inhibitors , Animals , Cell Count , Cells, Cultured , DNA Fragmentation/drug effects , Dipeptides/therapeutic use , Drug Interactions , Embryo, Mammalian , Microscopy, Electron, Transmission/methods , Neurons/physiology , Neurotoxicity Syndromes/drug therapy , Oxidative Stress/physiology , Peptide Fragments/antagonists & inhibitors , Propidium , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...